Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Blue Citrus** is an orally administered, multi-herb Chinese herbal medicine formulation evaluated by Legacy Health as supportive care for musculoskeletal pain associated with aromatase inhibitor therapy in postmenopausal patients with estrogen receptor-positive breast cancer. Its individual herbal constituents and molecular targets have not been publicly disclosed. In the completed randomized, double-blind, placebo-controlled crossover study NCT00702858, Blue Citrus was administered as five 700 mg capsules three times daily for three months and was associated with lower patient-reported pain scores than placebo.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Blue Citrus.